Publication Name	World Journal of Clinical Oncology
Manuscript ID	86914
Country	United States

Received	2023-07-13 19:45
Peer-Review Started	2023-07-13 20:33
To Make the First Decision
Return for Revision	2023-09-26 09:19
Revised	2023-10-13 22:33
Second Decision	2023-10-27 07:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-10-30 07:30
Articles in Press	2023-10-30 07:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-11-16 05:30
Publish the Manuscript Online	2023-11-22 04:14

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Autoimmune diabetes from pembrolizumab: A case report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Hardikkumar Bhanderi, Farhan Khalid, Zubair Hassan Bodla, Tayyeb Muhammad, Doantrang Du and Trishala Meghal
Funding Agency and Grant Number
Corresponding Author	Hardikkumar Bhanderi, MD, Staff Physician, Internal Medicine, Monmouth Medical Center, 300 2nd Avenue, Long branch, NJ 07740, United States. dr.hardikkumar.bhanderi@gmail.com
Key Words	Pembrolizumab; Breast cancer; Autoimmune diabetes; Keytruda; Immunotherapy; Case report
Core Tip	Our review highlights an important and rare adverse effect of Pembrolizumab. We have also reviewed the number of cycles patients were treated with Keytruda before the onset of diabetes. Clinicians should be watchful for the signs and symptoms. Early discontinuation of immunotherapy is needed to prevent significant morbidity and mortality.
Publish Date	2023-11-22 04:14
Citation	Bhanderi H, Khalid F, Bodla ZH, Muhammad T, Du D, Meghal T. Autoimmune diabetes from pembrolizumab: A case report and review of literature. World J Clin Oncol 2023; 14(11): 535-543
URL	https://www.wjgnet.com/2218-4333/full/v14/i11/535.htm
DOI	https://dx.doi.org/10.5306/wjco.v14.i11.535

Full Article (PDF)	WJCO-14-535-with-cover.pdf
Full Article (Word)	WJCO-14-535.docx
CARE Checklist–2016	86914-Scientific editor work list.pdf
Manuscript File	86914_Auto_Edited-LJH-JLW.docx
Answering Reviewers	86914-Answering reviewers.pdf
Audio Core Tip	86914-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	86914-Conflict-of-interest statement.pdf
Copyright License Agreement	86914-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	86914-Informed consent statement.pdf
Peer-review Report	86914-Peer-review(s).pdf
Scientific Misconduct Check	86914-Bing-Liu JH-2.png
Scientific Misconduct Check	86914-CrossCheck.png
Scientific Editor Work List	86914-Scientific editor work list.pdf